Track market-moving stories before they get noisy

ORLANDO, Fla.--(BUSINESS WIRE)--U.S. News & World Report named Travel + Leisure Co. to its 2026-2027 list of Best Companies to Work For.

SAN FRANCISCO--(BUSINESS WIRE)--Pottery Barn Kids, portfolio brand of Williams-Sonoma, Inc. (NYSE: WSM), the world's largest digital-first, design-led and sustainable home retailer, announced a new collaboration with popular children's clothing brand, Rylee + Cru. Founded in San Diego in 2014 by illustrator Kelli Murray Larson, Rylee + Cru is beloved for its charming clothing designs that feature artistic hand-illustrated prints and timeless earth-tone palette. The new Rylee + Cru for Pottery Ba.

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that Weight Watchers Med+ will support Medicare members seeking access to GLP-1 medications under the Medicare GLP-1 Bridge Program.

Through the Medicare GLP-1 Bridge Program, eligible beneficiaries purchase GLP-1 medications for weight loss, including Zepbound®, KwikPen®, Foundayo®, and Wegovy® pen and pill, for $50 per month. The program will run from July 1, 2026 through December 31, 2027. In addition to prescribing medication when appropriate and managing care for these medications, Weight Watchers helps Med+ members navigate insurance coverage, paperwork, and prior authorizations so they can easily access care.

“For many people, weight loss is about health, mobility and being able to keep doing the things they love. At Weight Watchers, our goal is to make the process feel less overwhelming by helping members understand their options, access care and receive a GLP-1 prescription if they’re eligible, while also providing the support they need to live well on treatment,” said Scott Honken, PharmD, Chief Commercial Officer, Weight Watchers.

To qualify for the Medicare Bridge program, you must have Medicare Part D, meet clinical eligibility, and have a prescription for an eligible GLP-1 medication. This medication must be used alongside ongoing lifestyle changes, including nutrition and physical activity, to support weight loss and maintenance.

As Medicare beneficiaries consider GLP-1 treatment, Weight Watchers, a trusted brand for older adults on their health journey, offers comprehensive care beyond providing a prescription. Our Med + program blends clinical oversight with behavioral tools to deliver sustainable results. In addition to clinical care, members access nutrition support, medication tracking, refill reminders, and expert GLP-1 coaches through our integrated GLP-1 Success Program. Crucially for older adults, the program includes tailored strength-building guidance to preserve muscle mass and reduce the risk of frailty and falls.

Weight Watchers data show that Med+ members prescribed a GLP-1 medication who regularly engaged with the GLP-1 Success Program lost 29.1% more body weight on average at 12 months than those who did not engage in behavioral support.1 In addition, 73% of Med+ members given the GLP-1 Success Program say that Weight Watchers Med+ helps minimize weight-loss medication side effects.2

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact::
Melissa Garbayo
[email protected]

1 Based on an internal analysis of 3,325 members who requested at least 1 GLP-1 medication refill through Weight Watchers Med+ and self-reported both a starting weight and weight at week 52. On average, members who logged in to the GLP-1 Success Program at least 4 days each week (n=376) lost 22.20% body weight, and members who never logged in to the app (n=2,949) lost 17.20% body weight in 52 weeks. Not a randomized, controlled clinical trial. Self-reported outcomes have not been independently verified. Individual results may vary.
2 Based on an internal data analysis of 92,160 members who received a treatment plan, were prescribed an injectable GLP-1 medication through Weight Watchers, and recorded their starting weight and completed a weigh-in 4 weeks after starting their treatment plan.

Companies in the financial sector can be great income investments. They tend to generate substantial recurring cash flow, providing them with the stable funds to pay durable dividends. Many financial stocks also pay higher-yielding dividends that steadily grow.

Here are three high-yielding financial stocks built to pay reliable dividends.

Image source: Getty Images.

Brookfield Asset Management Brookfield Asset Management (BAM 0.16%) is a leading global alternative investment manager. The company has over $1 trillion in assets under management across infrastructure, energy, private equity, real estate, and credit. Brookfield generates stable and steadily rising fee-based earnings by managing client assets. It has booked $3.1 billion in fee-related earnings over the last 12 months, up 18% year over year.

With stable earnings and minimal capital requirements, Brookfield aims to pay out about 95% of its fee-related earnings in dividends each year. Its payout currently yields 4.5%, putting it several times higher than the S&P 500 (1.1% yield).

Today's Change

(

-0.16

%) $

-0.07

Current Price

$

43.94

Brookfield expects to grow its fee-related earnings at a 17% compound annual rate through 2030, driven by a more than 16% compound annual growth rate in its fee-bearing capital base as it expands its current investment strategies and launches new ones. That should support annual dividend growth of more than 15%.

Realty Income Realty Income (O 0.84%) is one of the world's largest real estate investment trusts (REITs). It owns a diversified portfolio of retail, industrial, gaming, and other properties secured by long-term net leases with many of the world's leading companies. Net leases generate stable rental income because tenants cover all property operating costs, including routine maintenance, real estate taxes, and building insurance.

Today's Change

(

-0.84

%) $

-0.53

Current Price

$

62.24

The REIT pays out around 70% of its stable cash flow via its monthly dividend, which currently yields over 5%. Realty Income uses the cash flow it retains to invest in additional income-generating real estate.

The company's strategy has enabled it to pay a stable and steadily rising dividend. Realty Income has increased its monthly dividend 135 times since its public market listing in 1994, including for the last 115 quarters in a row (4.1% average annual growth rate). With over $14 trillion of real estate suitable for net leases across the U.S. and Europe, Realty Income has a long runway to continue growing its portfolio and dividend.

Main Street Capital Main Street Capital (MAIN +1.08%) is a business development company (BDC). It provides customized debt and equity capital solutions to lower-middle-market companies ($10 million to $150 million in revenue). It also provides debt capital to companies owned by or in the process of being acquired by a private equity fund (with under $500 million in revenue). These high-yielding loans generate recurring interest income, while the equity investments provide dividend income and potential capital appreciation.

Today's Change

(

1.08

%) $

0.55

Current Price

$

51.56

As a BDC, Main Street Capital must distribute 90% of its taxable income to investors via dividends. It does this through two payments. Main Street Capital pays a monthly dividend set at a sustainable level. It has never reduced this dividend. Instead, it has grown by 160% since its 2007 IPO, including 12 increases since the fourth quarter of 2021. At the current rate, Main Street's monthly dividend yields over 6%.

Additionally, the BDC periodically pays supplemental quarterly dividends. It has paid one for the last 19 consecutive quarters, while maintaining the current rate since early 2024. When added to the monthly payments, Main Street Capital's current annualized dividend yield is over 8.5%.

Bankable income streams Brookfield Asset Management, Realty Income, and Main Street Capital pay high-yielding dividends backed by stable and growing cash flows. That should enable these financial companies to continue growing their dividends going forward. They're ideal dividend stocks to buy for those seeking an income stream they can bank on in the years to come.

, /PRNewswire/ -- PPL Corporation (NYSE: PPL) today announced that Kenneth M. Hartwick, a veteran energy industry executive, will join its Board of Directors, effective July 1, 2026. He will serve on the People and Compensation Committee and Finance Committee of the Board.  With Hartwick's appointment, PPL's board continues to reflect a broad mix of skills and experiences aligned with the company's strategic priorities.

"Ken's deep experience across the energy sector, including his leadership as both a utility CEO and CFO, will further strengthen our board," said Craig A. Rogerson, independent Chair of PPL's Board of Directors. "His strategic insight, financial and risk management expertise, and experience overseeing large-scale generation and infrastructure investments will be invaluable as we continue to execute our strategy and deliver for our customers and shareowners."

Hartwick most recently served as president and chief executive officer of Ontario Power Generation from 2019 to 2025, during which he led the company's strategic growth and operational performance, including oversight of major generation investments; nuclear, natural gas combined-cycle, hydroelectric and solar operations; and energy transition initiatives. Prior to that, he served as Ontario Power's chief financial officer and held executive leadership roles at Wellspring Financial Corporation, Just Energy Group and Hydro One. He began his career with Ernst & Young, where he became a partner advising clients in the energy and utilities sector.

Hartwick currently serves on the boards of MYR Group Inc., where he is board chair, Denison Mines Corp., Independent Electricity System Operator of Ontario and the Investment Management Corporation of Ontario.

With Hartwick's appointment, PPL's board will consist of 10 directors. In addition to Rogerson as independent Chair, the board includes eight other independent directors and PPL's president and chief executive officer.

About PPL
PPL Corporation (NYSE: PPL), headquartered in Allentown, Pennsylvania, is a leading U.S. energy company focused on providing electricity and natural gas safely, reliably and affordably to more than 3.6 million customers in the U.S. PPL's high-performing, award-winning utilities are addressing energy challenges head-on by building smarter, more resilient and more dynamic power grids and advancing sustainable energy solutions. For more information, visit www.pplweb.com. 

Contacts: For news media: Ryan Hill, 610-774-4033

SOURCE PPL Services Corporation

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of LCI Industries (NYSE: LCII) to Patrick Industries, Inc. for 1.2440 shares of Patrick common stock for each share of LCI Industries common stock.Halper Sadeh encourages LCI Industries shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigati.

Choosing between Recursion Pharmaceuticals (RXRX +4.83%) and Summit Therapeutics (SMMT +2.21%) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candidate.

Both companies operate in the high-stakes world of biotechnology, but they take very different paths toward drug development. While Recursion focuses on an industrial-scale platform to find many targets, Summit is betting heavily on the success of a single, promising antibody therapy.

Recursion Pharmaceuticals operates as a TechBio company, using its proprietary Recursion OS to automate biological experiments and analyze them with artificial intelligence. The company generates vast amounts of proprietary data to identify potential treatments for oncology, rare diseases, and neuroscience. It works with several major biotech stocks through strategic collaborations, including Roche (RHHBY +1.62%), Genentech, Takeda (TAK +0.44%), Bayer (BAYRY 1.73%), Merck (MRK +0.56%), and Sanofi (SNY +1.12%). Customer concentration in these large-scale partnerships adds a layer of risk to the business, as revenue depends on the continued health of these specific alliances.

In fiscal 2025, revenue reached nearly $74.7 million, good for growth of about 26.9% year over year. Despite this growth, the company reported a net loss of close to $644.8 million. This reflects the high cost of maintaining its massive computing infrastructure and advancing a broad pipeline of investigational medicines through various stages of development.

As of Recursion’s December 2025 balance sheet, the debt-to-equity ratio stands at roughly 0.1x, which measures total debt against shareholder equity and indicates a very low level of borrowing. The current ratio is approximately 5.5x, meaning the company has five and a half times more short-term assets than short-term liabilities to cover its immediate obligations. Free cash flow was negative at nearly $378.3 million for the year, which is pretty common for clinical-stage companies investing heavily in future research.

The case for Summit TherapeuticsSummit Therapeutics is a biopharmaceutical company primarily focused on developing ivonescimab, a bispecific antibody designed to treat various types of solid tumors. The company’s core strategy revolves around a licensing agreement with Akeso (AKESF 4.54%), which grants Summit the rights to develop and commercialize this lead candidate in major global territories including North America and Europe. Because the company’s future depends almost entirely on this one drug, its commercial success is highly concentrated on clinical trial outcomes and the relationship with its supply partner.

In fiscal 2025, the company reported no revenue, as it doesn’t yet have products for sale. The net loss for the year was approximately $1.1 billion, a significant increase from previous periods. This high level of spending is largely due to the expensive late-stage clinical trials required to prove the efficacy and safety of ivonescimab to regulatory agencies.

As of Summit’s December 2025 balance sheet, the debt-to-equity ratio is zero, meaning the company carries no debt relative to its shareholder equity. Its current ratio is nearly 9.9x, which shows a very strong ability to meet short-term financial commitments with existing cash and assets. Free cash flow for the period was negative at close to $240.2 million, reflecting the ongoing costs of drug development without any incoming product revenue.

Risk profile comparisonRecursion Pharmaceuticals faces risks related to its significant history of operating losses, including an accumulated deficit of roughly $2.1 billion. There is no guarantee that its AI-driven platform will successfully produce approved drugs, and the company requires substantial new capital to continue its operations. Furthermore, the business relies on third-party manufacturers and strategic partners, and any issue with these relationships or disruptions in the supply chain could hinder development.

Summit Therapeutics is heavily exposed to concentration risk, as its business value is almost entirely tied to ivonescimab. If this single candidate fails in clinical trials or does not receive regulatory approval, the company would be would be up a creek without a paddle. Additionally, Summit has massive future financial obligations to its partner Akeso, including potential payments of up to $4.56 billion, and faces stiff competition from established oncology giants like Merck and Bristol-Myers Squibb (BMY +1.81%).

Valuation comparisonRecursion Pharmaceuticals currently trades at a high multiple of its revenue, while Summit Therapeutics has no price-to-sales ratio due to its lack of product sales.

MetricRecursion PharmaceuticalsSummit TherapeuticsP/S ratio19.3N/ASector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?I think Recursion Pharmaceuticals looks more attractive here. It posted a significantly smaller loss in its most recent fiscal year, and the company has multiple big-name partnerships currently employing its proprietary system. There is no guarantee Recursion's platform is going to produce anything that moves the needle, but I like that it has diversification among clients (and therefore, presumably among drugs). Plus, I don't think pharma giants like Merck or Sanofi are at risk of going out of business.

On the other hand, Summit is basically betting the house on ivonescimab. That concentration risk is not a thing I would go in for. It has plenty of dry powder, sure, but it's all being directed toward one place. If this single drug candidate fails, I'm not sure if Summit could pivot to something else, and even if it could, how long that might take. Furthermore, Summit relies on a single partnership, unlike Recursion, which has multiple companies it's teaming up with.

QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

NEWARK, Del.--(BUSINESS WIRE)--Sallie Mae today announced the launch of a new Parent Loan designed to give families an additional, flexible option to pay for higher education as federal student loan options evolve. The Sallie Mae® Parent Loan allows credit-qualified individuals, including parents, guardians, or significant others, to support the financing of undergraduate and graduate education for students and offers competitive interest rates that can be lower than federal Parent PLUS loans,.

June 30, 2026 08:30 ET  | Source: Ascendis Pharma

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. The data were presented by Leanne M. Ward, M.D., FRCPC, Professor of Pediatrics at the University of Ottawa and Children's Hospital of Eastern Ontario, during the 12th International Conference on Children's Bone Health (ICCBH 2026) held in Montreal, Canada.

“These results show that continuous exposure to active C-type natriuretic peptide (CNP) provided by once-weekly TransCon CNP positively affected skeletal growth and lower limb alignment in children with achondroplasia, with the potential to address serious complications of skeletal dysplasia that contribute to chronic pain, altered mobility, and need for surgical intervention,” said Dr. Ward. “These outcomes reinforce previously reported data showing TransCon CNP’s ability to support healthy and proportional growth, further highlighting its potential to advance pharmacological treatment for achondroplasia.”

ApproaCH Trial Design
ApproaCH was a randomized, double-blind, placebo-controlled pivotal trial in 84 children with achondroplasia aged 2–11 years, investigating TransCon CNP (100 µg/kg once-weekly) versus placebo for 52 weeks, followed by an open-label extension (OLE) in which all participants received TransCon CNP through Week 104. Radiographic assessments of lower extremity alignment were conducted at baseline, Week 52, and Week 104.

Highlights of Radiographic Assessments at Week 104 of the Pivotal ApproaCH Trial

Improvements in TFA and TFA Z-scores continued through Week 104 and were greater in children with baseline TFA ≥ 5°: The average TFA in all children treated with TransCon CNP during the double-blind period was 9.1° at baseline, decreasing to 7.7° at Week 52 and 6.9° at Week 104, reflecting a mean absolute change of -2.2 degrees over the two-year treatment period. In the subgroup of children with baseline TFA ≥ 5° (reflecting children with preexisting genu varum), the average TFA was 13.4° at baseline, decreasing to 11.3° at Week 52 and 9.6° at Week 104, reflecting a mean absolute change of -3.8 degrees over the two-year treatment period.The average TFA in children switching from placebo to TransCon CNP treatment at Week 52 was 11.5° at baseline, increasing to 11.8° at Week 52 and decreasing with TransCon CNP treatment to 10.1° at Week 104, reflecting a mean absolute change of -1.7 degrees during the OLE period. In the subgroup of children with baseline TFA ≥ 5°, the average TFA was 18.2° at baseline, increasing to 18.7° at Week 52 and decreasing with treatment to 14.9° at Week 104, reflecting a mean absolute change of -3.8 degrees during the OLE period.In children treated with TransCon CNP in the double-blind period, mean TFA Z-score was 3.62 at baseline and decreased to 3.15 at Week 52 and 2.96 at Week 104, reflecting a mean absolute change of -0.66 over the two-year treatment period. In the subgroup of children with baseline TFA ≥ 5°, mean TFA Z-score was 5.40 at baseline and decreased to 4.67 at Week 52 and 4.36 at Week 104, reflecting a mean absolute change of -1.04 over the two-year treatment period.In children switching from placebo to TransCon CNP at Week 52, mean TFA Z-score was 4.08 at baseline, increased to 4.76 at Week 52, and decreased to 4.28 at Week 104, reflecting a mean absolute change of -0.48 from Week 52 to Week 104. In the subgroup of children with baseline TFA ≥ 5°, mean TFA Z-score was 6.13 at baseline, increased to 7.56 at Week 52, and decreased to 6.35 at Week 104, reflecting a mean absolute change of -1.21 from Week 52 to Week 104. Results also showed that fibula-to-tibia length ratio remained stable in the overall clinical trial population during the open-label extension, reflecting proportional growth of the lower leg. Through up to two years of treatment, TransCon CNP was generally well tolerated, with a low rate of ISRs (all mild), no symptomatic hypotension, and no acceleration of bone age. Most adverse events in TransCon CNP-treated children were mild or moderate, with none leading to treatment discontinuation or withdrawal from the trial.

A slide presentation with these data will be made available on the Investors & News section of the Ascendis Pharma website: https://investors.ascendispharma.com.

About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, and is associated with an increased risk of muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia can vary from individual to individual and across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and reduced stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; some of which persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) TransCon CNP’s ability to address serious complications of skeletal dysplasia, including those that contribute to chronic pain, altered mobility, and need for surgical intervention, (ii) TransCon CNP’s ability to deliver healthy and proportional growth and its potential to advance pharmacological treatment of achondroplasia, (iii) the anticipated timing of a regulatory decision by the European Medicines Agency regarding YUVIWEL, (iv) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (v) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © June 2026 Ascendis Pharma A/S.

Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875

Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall survival as approval endpoint Biomarker data submitted to FDA BEST program as surrogate clinical efficacy data Synthetic historical control arm OST-400 recruitment potentially adds comparator for BLA submission under the Accelerated Approval Review of Rolling Review, RMAT & Breakthrough Therapy designation requests sought New York, New York and Rockville, Maryland--(Newsfile Corp. - June 30, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Food and Drug Administration (FDA) in its pursuit of a Biologics License Application (BLA) under the Accelerated Approval Program (Accelerated Approval) for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"). OS Therapies has requested a Type B Meeting to review the Company's 2.5-year overall survival data and to confirm alignment that 3-year overall survival data is an approvable clinical efficacy endpoint.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027. The sNDA.

AI-powered solution provides residents with 24/7 multilingual access to trusted state government information

PLANO, Texas--(BUSINESS WIRE)--Tyler Technologies, Inc. (NYSE: TYL) successfully launched its Resident AI Assistant in South Carolina to improve the speed at which residents can access information. The assistant, named “Bradley,” acts as a centralized, conversational gateway to South Carolina’s government services, delivering answers sourced directly from verified .gov websites across state agencies.

“South Carolina supports more than five million residents across dozens of state agencies, each with its own programs and websites,” said Nathan Hogue, state chief information officer for the South Carolina Department of Administration. “Bradley gives residents a single, trusted starting point for government information. Whether they need DMV guidance, court resources, or tax assistance, Bradley helps them find accurate answers in seconds, allowing our staff to focus on more complex service needs.”

Home to more than five million residents across 46 counties, South Carolina continues to invest in digital government services. The statewide launch of Bradley reflects the state’s commitment to expanding access to government resources through secure, purpose-built technology designed for the public sector.

Since launching in September 2025, Bradley has demonstrated a strong impact, including:

More than 38,000 questions answered from over 10,800 unique users An average of 195 questions resolved per day, peaking at 426 in a single day An 82.2% first-contact resolution rate, with most inquiries answered in one exchange 24/7 availability, with 15% of interactions occurring on weekends and significant after-hours usage Support for 54 languages, with approximately 6% of interactions in non-English languages By retrieving information exclusively from verified South Carolina government websites,

Bradley provides residents with real-time, trusted responses. The solution also delivers actionable analytics that give the state visibility to resident needs, such as vehicle services, legal and court information, and tax information. These insights help the state make data-driven improvements to content, processes, and service delivery.

“Tyler’s Resident AI Assistant is designed specifically for government, with safeguards, transparency, and analytics that go well beyond a traditional chatbot,” said Liz Thomas, president of Tyler’s State & Federal Group. “By centralizing resident access, South Carolina is delivering a more responsive, efficient, and accessible government experience.”

About Tyler Technologies, Inc.

Tyler Technologies (NYSE: TYL) is a leading provider of technology solutions purpose-built exclusively for the public sector. Tyler’s end-to-end solutions empower local, state, and federal government entities to operate efficiently and transparently with residents and each other. By connecting data and processes across disparate systems, Tyler’s solutions strengthen the core operations of government and help agencies turn insight into action for their communities. With more than 50,000 installations across 16,000 client locations, Tyler serves clients in all 50 states, Canada, the Caribbean, Australia, and other international locations. Tyler has been recognized numerous times for growth and innovation, including on Government Technology’s GovTech 100 list. More information about Tyler Technologies, an S&P 500 company headquartered in Plano, Texas, can be found at tylertech.com.

#TYL_General

Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027.

RICHMOND, Va.--(BUSINESS WIRE)--Advisory for quarterly earnings call.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Back on December 27, 2025, we wrote about J.P. Morgan’s three overweight picks for 2026 with the highest implied upside: Bright Horizons Family Solutions (NYSE: BFAM | BFAM Price Prediction), Celsius (NASDAQ: CELH), and GE Vernova (NYSE: GEV). At the halfway point of the year, the scoreboard tells a counterintuitive story. The pick with the lowest percentage upside, GE Vernova, has cleared its target. The two names J.P. Morgan flagged with the largest implied gains have moved in the other direction.

We compared each stock’s move since the original call to J.P. Morgan’s full-year 2026 target, weighing operational drivers, beat-and-raise cadence, and Wall Street’s current consensus. Counting down from worst to best:

3. Bright Horizons Family Solutions J.P. Morgan had a 2026 price target of $160 for this stock. Shares closed at $70.89 on June 29, 2026, leaving it down 30.1% year to date. That is the deepest hole of the trio.

The Q4 2025 report looked fine on the surface, with adjusted EPS of $1.15 versus $1.12 consensus and revenue of $733.70 million. The problem: management disclosed plans to close 45 to 50 centers in 2026, nearly double the prior estimate, paired with $45.1 million in impairment and lease-termination charges. Multiple law firms initiated securities fraud investigations after the revision. Labor-market softness and enrollment pressure in full-service child care have hit the thesis hard, even as Back-Up Care generated more than $725 million in 2025 revenue.

Wall Street still carries an analyst target of $91.11, the forward P/E is 15x, and FY 2026 guidance calls for adjusted EPS of $4.90 to $5.10 on revenue of $3.075 billion to $3.125 billion. The setup is reset-to-recover, but the J.P. Morgan target looks out of reach without a clean operational quarter.

2. Celsius J.P. Morgan’s Celsius target was $68. Shares finished at $29.79 on June 29, 2026, down 34.9% since the beginning of the year. The frustrating part is that fundamentals are working. Q1 2026 delivered revenue of $782.62 million, up 137.7% year over year, beating consensus by 2.89%, with EPS of $0.41 versus the $0.293 estimate. Celsius reached a 20.9% dollar share of the U.S. energy drink category.

The market punished integration noise. Folding Alani Nu into PepsiCo’s distribution network compressed gross margin to 48.3% from 52.3%, Rockstar retail sales declined 13%, and a $24.6 million legal settlement accrual showed up in the quarter. CEO John Fieldly framed it as “a defining period for Celsius Holdings.”

SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.

Wall Street still carries an analyst target of $58.52 with 20 Buy or Strong Buy ratings against zero Sell ratings, and the forward P/E has compressed to 19x. J.P. Morgan’s $68 target is roughly the old high-water target, and clearing it requires margin recovery to the low-50s that management has guided toward.

1. GE Vernova GE Vernova was the lowest-implied-upside pick of the three, and it is the runaway winner. J.P. Morgan’s $1,000 target has already been cleared: shares closed at $1,102.51 on June 29, 2026, up 68.7% year to date and 112.2% over the trailing year.

The driver is the AI and data-center power buildout. Q1 2026 revenue of $9.30 billion grew 15.8% year over year, with orders surging 71% organically to $18.30 billion. Electrification booked $2.40 billion in data-center equipment orders in Q1 alone, exceeding all of 2025. Backlog reached a record $150 billion in Q4 2025, and management is targeting 110-plus GW of combined gas turbine backlog and slot reservation agreements by year-end 2026. The 2026 guidance was raised again: revenue of $44.5 billion to $45.5 billion, adjusted EBITDA margin of 12% to 14%, and free cash flow of $6.5 to $7.5 billion.

CEO Scott Strazik said, “Demand is accelerating for our Power and Electrification solutions from a diverse set of customers, with our backlog growing by more than $13 billion quarter-over-quarter.” The consensus analyst target of $1,211.72 is just above current levels, the forward P/E is 37x, and shares trade 7% below the 52-week high of $1,181.95. The thesis is intact; the easy money is already on the table.

The Halftime Verdict J.P. Morgan’s lowest-upside name carried the franchise. GE Vernova’s year-to-date move blew through the $1,000 price target, while Bright Horizons and Celsius, the two picks with the most implied upside, have undercut their targets by a wide margin. Secular tailwinds like AI-driven power demand can outrun even the most aggressive Wall Street price targets, while consumer and services names dependent on labor markets and brand integrations can stall regardless of how compelling the entry-point math looked in December.

Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.

From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus. 

Contact [email protected] for any questions or corrections.

Key Highlights Table of Contents

Key HighlightsStrategic Acquisition Delivers Critical Sodium Technology CapabilitiesTransaction Accelerates Development Timeline and Mitigates Technical UncertaintiesTransaction Expands Oklo’s Comprehensive Nuclear Technology EcosystemGet 3 Free Stock Ebooks OKLO climbs in pre-market sessions following 1.19% gain to reach $53.39

Company acquires Creative Engineers to enhance Aurora reactor sodium capabilities

Transaction delivers liquid-metal expertise, manufacturing capacity, and validation capabilities

Approximately 20 specialized professionals join Oklo’s technical workforce

Strategic move accelerates timeline and minimizes development uncertainties

Shares of Oklo Inc. (OKLO) advanced in early trading following the company’s announcement of its Creative Engineers, Inc. acquisition, which enhances its sodium engineering capabilities for the Aurora powerhouse initiative. The stock increased 1.19% to $53.39 in pre-market activity after finishing the previous session 5.52% higher at $52.76. This strategic transaction provides Oklo with enhanced oversight of critical liquid-metal technologies as commercialization approaches.

Strategic Acquisition Delivers Critical Sodium Technology Capabilities Oklo announced that the transaction incorporates CEI’s chemical process engineering capabilities into its advanced nuclear technology platform. The acquisition delivers enhanced competencies in sodium-based systems, manufacturing operations, component engineering, and applied scientific research. Consequently, this strategic move directly reinforces the technical infrastructure supporting Oklo’s sodium-cooled Aurora reactor platform.

Creative Engineers brings nearly three decades of specialized experience with sodium, sodium-potassium compounds, and lithium-based systems since establishing operations in 1996. The firm’s portfolio encompasses remediation and deactivation activities associated with prominent nuclear sodium initiatives. These landmark projects include the Fast Flux Test Facility, Fermi 1, and Experimental Breeder Reactor II programs.

The relationship between Oklo and CEI extends back multiple years prior to this formal acquisition. Previous collaborative efforts encompassed sodium circulation systems, measurement instrumentation, pumping equipment, and specialized safety protocols. Therefore, Oklo is now integrating a proven technical collaborator directly into its core development operations.

Transaction Accelerates Development Timeline and Mitigates Technical Uncertainties Oklo anticipates that CEI will enable accelerated engineering processes and improved availability of sodium-handling competencies. The company further projects that this acquisition will minimize uncertainties surrounding specialized infrastructure, validation procedures, manufacturing operations, and workforce development. This strategic importance stems from sodium systems serving as foundational components in Aurora’s planned commercialization strategy.

The Aurora platform utilizes a sodium-cooled fast reactor architecture featuring liquid-metal thermal management and inherent safety mechanisms. The engineering approach incorporates natural convection principles to facilitate residual heat dissipation following reactor shutdown. CEI’s specialized sodium experience aligns precisely with Oklo’s reactor development and operational deployment requirements.

The acquisition delivers approximately 20 specialized professionals—including engineers, manufacturing technicians, and welding specialists—to Oklo’s technical and production operations. The business unit also contributes positive free cash flow generation, according to company statements. CEI will maintain service relationships with its established commercial clients throughout the nuclear industry.

Transaction Expands Oklo’s Comprehensive Nuclear Technology Ecosystem Oklo focuses on developing fast fission energy systems designed to deliver clean, dependable, and economically viable power generation on a worldwide scale. The organization also pursues critical isotope production capabilities and advanced nuclear fuel reprocessing technologies. Its fuel recycling strategy targets the conversion of spent nuclear materials into viable energy resources.

The company maintains a site authorization permit issued by the U.S. Department of Energy for advanced fission facility deployment. It has also obtained fuel materials from Idaho National Laboratory to support its development initiatives. Oklo has filed a customized combined license application with the U.S. Nuclear Regulatory Commission.

Creative Engineers functions as a process engineering and modular fabrication enterprise with specialized reactive metals proficiency. Its operational scope encompasses pilot-scale research apparatus, liquid-metal infrastructure, and chemical manufacturing systems. Through this transaction, Oklo reinforces its Aurora development trajectory while simultaneously acquiring specialized nuclear production capabilities.

Oliver Dale

Editor-in-Chief of Blockonomi and founder of Kooc Media, A UK-Based Online Media Company. Believer in Open-Source Software, Blockchain Technology & a Free and Fair Internet for all. His writing has been quoted by Nasdaq, Dow Jones, Investopedia, The New Yorker, Forbes, Techcrunch & More. Contact [email protected]

SANTA ANA, Calif.--(BUSINESS WIRE)--First American Data & Analytics, a leading national provider of property-centric information, risk management and valuation solutions and a division of First American Financial Corporation (NYSE: FAF), today released its May 2026 Home Price Index (HPI) report. The report tracks home price changes less than four weeks behind real time at the national, state and metropolitan (Core-Based Statistical Area) levels and includes metropolitan price tiers that seg.

Progress Chef brings enterprise-grade secure configuration management and governance to fleets of desktop AI supercomputers at scale

BURLINGTON, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), the trusted provider of AI-powered digital experience and infrastructure software, today announced that its Progress® Chef® platform now delivers enterprise lifecycle management and configuration capabilities for NVIDIA DGX Spark, enabling IT teams to securely provision, monitor and manage the desktop AI supercomputer at scale.

NVIDIA highlighted Progress Chef’s role in enabling enterprise management for DGX Spark earlier this month in its developer blog.

“DGX Spark is bringing powerful AI computing out of the data center and into the hands of developers across the enterprise,” said Sundar Subramanian, Executive Vice President and General Manager, Infrastructure Management at Progress Software. “As this new class of infrastructure scales, organizations must maintain confidence that every system remains secure, compliant and aligned with its intended state. Progress Chef provides the automation and governance needed to move quickly without losing operational control.”

NVIDIA DGX Spark delivers petaflop-class AI performance in a compact desktop system, combining advanced hardware with the NVIDIA AI software stack. Designed to put AI supercomputing directly in the hands of developers, DGX Spark enables teams to build, fine-tune and run AI models locally. As these systems expand across offices, research facilities, edge locations and regulated environments, enterprises must manage them with the same rigor as other critical infrastructure. NVIDIA identified Progress Chef as an enterprise manageability partner supporting DGX Spark deployments. 

Progress Chef enables IT and platform engineering teams to integrate DGX Spark into existing infrastructure operations and automate key lifecycle stages, including:

Consistent configuration: Establish and continuously maintain approved system configurationsFleet-wide visibility: Monitor system health, software inventory and configuration postureControlled maintenance: Orchestrate updates and operational changes across staged cohortsContinuous compliance: Detect configuration drift and validate adherence to security policiesGoverned automation: Enforce role-based access, approvals and auditable workflowsIncident response: Automate diagnostics and evidence collection across distributed systemsLifecycle management: Standardize processes from deployment through retirement NVIDIA DGX Spark Enterprise Manageability provides an operational framework spanning procurement, provisioning, monitoring, maintenance, incident response and retirement. Its agentless SSH execution model and standardized JSON output are designed to integrate with enterprise orchestration, monitoring, CMDB and security workflows. 

Progress Chef complements this framework by providing continuous convergence and governed orchestration across the fleet. Organizations can group systems into cohorts, introduce changes in controlled stages, detect drift and validate outcomes while preserving the flexibility developers need to experiment and innovate.

The support for NVIDIA DGX Spark further expands Progress’ infrastructure management capabilities into a fast-growing class of persistent AI infrastructure. It underscores Progress’ broader strategy to help organizations develop, deploy and manage AI securely and responsibly across their data, digital experiences and underlying infrastructure.

Pricing and Availability
Progress Chef Enterprise Management for NVIDIA DGX Spark is available immediately with an introductory pricing of $189 per year per system. For more information, visit Manage NVIDIA DGX Spark as Enterprise Infrastructure with Chef

About Progress Software  
Progress Software (Nasdaq: PRGS) empowers organizations to achieve transformational success in the face of disruptive change. Our software enables customers to develop, deploy and manage responsible AI-powered applications and personalized digital experiences with agility and ease. Businesses of all sizes rely on Progress for the products, expertise and vision they need to turn AI disruption into a competitive advantage. Millions of developers and technologists at hundreds of thousands of organizations depend on Progress every day. Learn more at www.progress.com.

Progress, Chef and certain product names used herein are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the U.S. and/or other countries. See Trademarks for appropriate markings. All rights in any other trademarks contained herein are reserved by their respective owners and their inclusion does not imply an endorsement, affiliation or sponsorship as between Progress and the respective owners.

Press Contact:            
Jeff Young
Progress Software
+1-800-477-6473
[email protected]

Michael Angelakis is one of a core group of co-CEO Brian Roberts's trusted advisers.

Comcast shares are soaring after the company announced plans to split its media and technology businesses.

Job gains were broad based while hourly earnings growth remains below three percent

ROCHESTER, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- The Paychex Small Business Jobs Index—a primary component of the monthly Paychex Small Business Employment Watch report—shows the pace of job growth among U.S. small businesses with fewer than 50 employees improved for the fourth consecutive month in June, matching its highest index level since August 2025 (99.83) and marking the first four-month consecutive increase since November 2020. While gains were broad based, increases across the West region (1.22 percentage points) and the Leisure & Hospitality sector (1.68 percentage points) helped drive the jobs index gains in June.

Meanwhile, hourly earnings growth for U.S. workers remains below three percent (2.80%). Weekly hours worked (0.14%) continued to trend positively for the fourth consecutive month, as weekly earnings growth in June reported 2.80%.

“The pace of small business job growth improved for a fourth consecutive month in June, matching its highest level since August 2025 and once again reinforcing the resilience of small businesses,” said John Gibson, Paychex president and CEO. “Broad-based momentum across most regions and many states, coupled with continued increases in weekly hours worked and earnings, signals steady demand for workers among small businesses as we move through summer.”

“The pace of employment growth across our overall client base improved again in June, with slightly stronger growth among those with 50 or more employees,” Gibson added.

Jobs Index and Wage Data Highlights

All regions increased their small business employment growth rate during the past quarter, with the largest three-month gain in the West (1.95 percentage points).All sectors improved their pace of small business employment growth during the past quarter, led by Leisure and Hospitality (1.69 percentage points). Education and Health Services topped sectors for small business job growth in June, while Leisure and Hospitality’s one-month surge from ranking sixth also helped lift industry’s jobs index level (99.55) to a two-year high.Indiana (101.46) reclaimed its role as the top state for small business employment growth, a position it has held for nine of the last 24 months.California’s jobs index (100.01) gained more than two percentage points during the past quarter to land above 100 in June – a first since March 2024.
About the Paychex Small Business Employment Watch
Since 2014, the Paychex Small Business Employment Watch has been a trusted source of employment trends for U.S. small businesses with fewer than 50 employees. The Employment Watch website offers interactive charts and historical data across the report’s two key components – the jobs index and wage data – as well as the methodology for both analyses. Visit the Bloomberg Terminals or subscribe to receive monthly alerts with the latest data.

*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.

About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 800,000 clients and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI platform embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.

Media Contacts
Tracy Volkmann
Paychex, Inc.
Manager, Public Relations
(585) 387-6705
[email protected]
@Paychex

Erin McAward
ICR, Inc.
Account Director
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9d2d3725-ffb7-4b07-b8d9-f54dd1333374

Integration of 2-10 and expansion with SkySlope have enhanced Frontdoor's real estate channel, supporting attach rate and organic growth despite macro headwinds. Frontdoor's pricing power, high retention, and non-warranty upsell growth drive a projected 5% revenue CAGR and improved EBITDA margin targets. Competitive threats, notably from Assurant, warrant caution; with shares at all-time highs and no near-term catalysts, I would wait for a better entry.

O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to care

O'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transition

, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets.

Mr. O'Reilly brings extensive healthcare compliance, risk management, regulatory oversight and legal experience across complex healthcare, insurance and clinical operations. He has led compliance programs supporting Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice and home health, value-based primary care and pharmacy benefit management organizations.

"Sean brings an exceptional combination of healthcare compliance leadership, operational and payer industry expertise, as well as M&A experience," stated Dario's Chief Executive Officer, Erez Raphael. "His perspective will be invaluable as we continue to expand Dario's relationships across the healthcare ecosystem, accelerate adoption of our AI-powered behavioral health and chronic multi-condition management platform, and move closer to care."

"Dario is operating in one of the most important areas of healthcare, where digital engagement, clinical impact, regulatory confidence and measurable value must come together," said Mr. O'Reilly. "The Company's platform is well aligned with the needs of health plans, providers and employers seeking scalable solutions that improve outcomes while supporting accountability and operational excellence. I look forward to working with Erez and the Dario team as the Company continues to expand its role across the healthcare ecosystem."

Prior to consulting in a prominent Healthcare Risk Management & Advisory practice, O'Reilly spent more than 13 years at Humana, including serving as Senior Vice President and Chief Compliance Officer, where he led enterprise compliance programs across Medicare Advantage, Medicaid, employer-sponsored health plans, pharmacy benefit management, home health, hospice, military healthcare and value-based care operations.

His experience leveraging advanced data analytics and AI to strengthen compliance oversight, operational performance and value-based care aligns closely with Dario's commitment to delivering measurable healthcare outcomes through innovative technology solutions.

Mr. O'Reilly is also a licensed attorney with a background in mergers and acquisitions. His work integrates privacy, ethics and technology-driven risk analysis to strengthen compliance culture, support operational integrity and enable strategic growth.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company's belief that Mr. O'Reilly's experience is expected to support the Company's continued expansion with health plans, employers and providers; the Company's belief that Mr. O'Reilly's appointment will strengthen its strategic guidance; the Company's expectation to continue advancing its channel partner-led growth strategy; the Company's future adoption of its AI-powered behavioral health and chronic multi-condition management platform; the Company's expectation to continue expanding its relationships across the healthcare ecosystem; the Company's expectation to continue expanding its role across the payer, provider and employer markets; the Company's belief its platform is well aligned with the needs of health plans, providers and employers; and the Company's belief its technology will continue to support measurable healthcare outcomes. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected]

Logo- https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

SOURCE DarioHealth Corp.

SAN JOSE, Calif., and DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Nutanix (NASDAQ: NTNX), a leader in hybrid multicloud computing, and the North Carolina School of Science and Mathematics (NCSSM), the number one public high school in the United States, today announced the establishment of the Nutanix Endowed Professorship in Computer Science. This endowment is funded by a one-time corporate grant of $250,000 from Nutanix and is dedicated to expanding high-quality computer science education statewide. The endowment is expected to be matched by state dollars in late 2026.

The Challenge: Bridging the Rural Digital Divide

Access to robust technical learning pathways remains uneven across North Carolina, particularly within rural and underserved communities. While the state's Department of Public Instruction enacted a mandate requiring high school students to pass a computer science course to graduate, localized funding for essential teacher training remains severely restricted.

The newly established Nutanix Endowed Professorship in Computer Science directly addresses this critical gap by supporting NCSSM initiatives in teacher training and provision of systemic open-source educational resources in North Carolina.

Scalable Impact Through Virtual Learning

NCSSM Computer Science faculty provide high-level computer science instruction to public schools across North Carolina. By equipping students and educators with the skills required to integrate computational thinking into their academic journeys, this initiative is designed to create a cascading positive effect that reaches thousands of students well beyond NCSSM's physical campuses.

A primary vehicle for scaling this endowment’s impact across the state is NCSSM Connect, an innovative educational outreach program that uses synchronous, high-definition video conferencing to deliver real-time, interactive STEAM (Science, Technology, Engineering, Arts, and Math) courses directly to public high school classrooms statewide. By streaming directly into local schools, NCSSM Connect enables students in rural and economically disadvantaged communities to take honors and AP-level computer science courses that their local schools might not otherwise be able to offer.

Tech as a Force for Good

“The grant lifts up communities that have historically lacked access to critical STEAM disciplines and shape the next generation of digital leaders,” said Jennifer Lepird, Chief People Officer at Nutanix. “We believe that innovation thrives when everyone has a seat at the table. Supporting this endowment reflects our commitment to using technology as a force for good by expanding access to computer science education in North Carolina - a place where many of our employees live and work.”

The endowment builds upon Nutanix's global philanthropy program, Nutanix Spark, which focuses on building “Well Communities” and nurturing student interest in STEAM education. Nutanix has a substantial and well-established presence in Durham, North Carolina. The location serves as one of Nutanix’s primary East Coast hubs, anchoring its operations in the Research Triangle region. Through the Nutanix Endowed Professorship in Computer Science, the company aims to continue shaping the future technology workforce and expanding access to high quality computer science education in North Carolina.

“NCSSM has always focused on removing economic barriers to advanced STEAM education; no student pays tuition to attend our school. Nutanix’s leadership gift significantly amplifies that mission,” said Todd Roberts, Chancellor at NCSSM. “By tying this endowment to our open-source curriculum model, Nutanix is helping us provide students and teachers in every corner of North Carolina - especially those in under-resourced rural areas - with the training and tools they need at no cost to them.”

Charles Robinson Appointed as the Endowed Professor

Charles Robinson will serve as Nutanix Endowed Professor of Computer Science at NCSSM. He joined NCSSM in August 2019 as an Instructor of Computer Science after working within the Durham school system since 2012 as a technology technician, high school Career and Technical Education (CTE) teacher, and instructional assistant. He holds a master's degree in instructional technology from North Carolina Central University. While he initially taught in NCSSM's residential program, he now teaches exclusively through NCSSM Connect. In this role, he delivers honors curriculum including Introduction to Computer Science, Intro to Artificial Intelligence and Computational Thinking, and Connected Computing reaching some 100 remote high school students across North Carolina each year.

“Through NCSSM Connect, my absolute focus is on teaching high school students across North Carolina, virtually entering their local classrooms to provide rigorous computer science education,” said Charles Robinson, Nutanix Endowed Professor of Computer Science at NCSSM. “This funding ensures we can expand our reach, spark deep student engagement, and empower young minds to lead confidently and ethically in the modern digital economy.”

Deepening a Decade Long Partnership

NCSSM has relied on the Nutanix Cloud Platform for over ten years. As NCSSM has grown, including expanding its physical footprint and digital reach across North Carolina, the school’s Nutanix infrastructure has scaled right alongside it.

“As a proud partner for over a decade, NCSSM is thrilled to be a longtime Nutanix customer. For more than 10 years, we have trusted Nutanix hardware and software solutions to host the essential server infrastructure powering both our Durham and Morganton campuses. This generous donation further strengthens a partnership dedicated to providing a reliable digital foundation for the next generation of STEAM leaders.” - Justin Fleming, NCSSM Chief Information Officer

Future Outlook and Implementation Timeline

The endowment process is expected to be fully completed over the next three years. However, immediate implementation steps include:

Fall 2026 Curriculum: Beginning this fall, six NCSSM Connect courses will be taught by Nutanix Endowed Professor of Computer Science Charles Robinson.Teacher Training Pilots: In anticipation of the endowment funds becoming available, the Engineering and Computer Science Department will explore opportunities in the upcoming year to pilot computer science teacher training initiatives.Advanced AI Ecosystems: The endowment expands on NCSSM's existing technical ecosystem, which includes the Ryden Program for Innovation and Leadership in AI, helping ensure that foundational data science and ethical computer science training remain ahead of the curve.
NCSSM has a storied history of cultivating world-changing pioneers, from Carl Ryden, whose vision helped establish the school's AI programming, to legendary alumna Christina Koch '97, the record-breaking astronaut and crew member for the Artemis II mission. The Nutanix Endowed Professorship of Computer Science paves the way for the next generation of North Carolina students to follow in these historic footsteps.

For more details on the program and how public high schools can access these open-source resources, visit https://www.ncssm.edu/ncssm-connect.

About NCSSM

North Carolina School of Science and Mathematics is a world-class public high school with statewide reach empowering students with the skills and knowledge to design their future. Specializing in science, technology, engineering, and math, and embracing the humanities and fine arts, NCSSM is one school with two campuses and a host of statewide program offerings. It challenges talented high school juniors and seniors from across North Carolina through its Residential program on its original campus in Durham and on a new campus that opened in Morganton in 2022. NCSSM’s Online program, virtual Connect courses, and summer offerings extend its transformative impact to every corner of the state and to younger students. Founded in 1980 as the first of its kind, NCSSM has become the model for 18 such specialized schools around the globe and is a member of the 17-institution University of North Carolina System. Its 15,000-plus alumni include local and global leaders in medicine, technology, commerce, education, and the arts – a community of problem solvers who build a brighter future.

About Nutanix

Nutanix is a hybrid multicloud computing leader, offering organizations a unified software platform for running applications and AI and managing data anywhere. With Nutanix, organizations can simplify operations for traditional and modern applications, freeing them to focus on business goals. Trusted by more than 30,000 customers worldwide, Nutanix helps empower organizations to transform digitally and power hybrid multicloud environments consistently, simply, and cost-effectively. Learn more at www.nutanix.com or follow us on social media.

© 2026 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. (“Nutanix”) in the United States and other countries. All other brand names or marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release is for informational purposes only and nothing herein constitutes a warranty or other binding commitment by Nutanix. Customer statements on results, benefits, savings or other outcomes depend on a variety of factors including their use case, individual requirements, and operating environments, and should not be construed to be a promise or obligation to deliver specific outcomes or as guarantees of future performance.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b785e846-8d3e-48bf-9596-35d94463b7d1

NCSSM Nutanix Endowed Professorship Charles Robinson, Nutanix Endowed Professor of Computer Science at the North Carolina School of Scie...